Liver Cirrhosis Research Today is a free monthly online journal that collates and summarizes the latest research about Liver Cirrhosis, including details on alcohol, treatment, drugs, effects, causes.

Volume 2 (2005), Issue 5 (May)

1. Antifibrotic effects of Salvia miltiorrhiza on dimethylnitrosamine-intoxicated rats.
   J Biomed Sci, 12(1): 185-95. [Abstract] [Full-text]
2. Spontaneous ruptured umbilical hernia in a child with hepatic cirrhosis and ascites.
   Pediatr Surg Int, 21(5): 413-4. [Abstract] [Full-text]
3. The role of Helicobacter spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis.
   FEMS Immunol Med Microbiol, 44(2): 221-5. [Abstract] [Full-text]
4. The plasticity of p19 ARF null hepatic stellate cells and the dynamics of activation.
   Biochim Biophys Acta, 1744(1): 76-87. [Abstract] [Full-text]
5. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B.
   Clin Transplant, 19(3): 321-6. [Abstract] [Full-text]
6. Circulating markers of oxidative stress and liver fibrosis in Sudanese subjects at risk of schistosomiasis and hepatitis.
   Acta Trop, 94(2): 99-106. [Abstract] [Full-text]
7. Effects of sympathetic nerves and angiotensin II on renal sodium and water handling in rats with common bile duct ligature.
   Am J Physiol Renal Physiol, 288(6): F1267-75. [Abstract] [Full-text]
8. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis.
   J Hepatol, 42(6): 914-9. [Abstract] [Full-text]
9. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells--a potential mechanism for targeting liver anti-fibrotic therapeutics.
   J Hepatol, 42(6): 888-96. [Abstract] [Full-text]
10. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score.
    J Hepatol, 42(6): 826-32. [Abstract] [Full-text]
11. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices.
    J Hepatol, 42(6): 820-5. [Abstract] [Full-text]
12. The quantification of cytochrome P-450 (CYP 3A4) mRNA in the blood of patients with viral liver diseases.
    Clin Biochem, 38(6): 531-4. [Abstract] [Full-text]
13. Quantitative treatment of the hyponatremia of cirrhosis.
    Dig Liver Dis, 37(3): 176-80. [Abstract] [Full-text]
14. Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations.
    Am J Physiol Gastrointest Liver Physiol, 288(6): G1135-43. [Abstract] [Full-text]
15. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis.
    Am J Physiol Gastrointest Liver Physiol, 288(6): G1292-300. [Abstract] [Full-text]
16. Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms.
    Dig Liver Dis, 37(6): 446-50. [Abstract] [Full-text]
17. High mortality rate in patients with advanced liver disease independent of exposure to general anesthesia.
    J Clin Anesth, 17(3): 172-6. [Abstract] [Full-text]
18. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
    Br J Pharmacol, 145(2): 166-77. [Abstract] [Full-text]
19. Value of computed tomography and magnetic resonance imaging for assessing severity of liver cirrhosis secondary to viral hepatitis.
    Eur J Radiol, 54(3): 400-7. [Abstract] [Full-text]
20. Doppler and gray-scale ultrasound evaluation of morphological and hemodynamic changes in liver vascualture in alcoholic patients.
    Eur J Radiol, 54(3): 393-9. [Abstract] [Full-text]
21. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms.
    J Pharmacol Exp Ther, 313(3): 952-61. [Abstract] [Full-text]
22. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis.
    Liver Int, 25(3): 657-66. [Abstract] [Full-text]
23. Chronic administration of aminoguanidine reduces vascular nitric oxide production and attenuates liver damage in bile duct-ligated rats.
    Liver Int, 25(3): 647-56. [Abstract] [Full-text]
24. Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I:C administration.
    Liver Int, 25(3): 595-603. [Abstract] [Full-text]
25. Octreotide in liver cirrhosis: a salvage for variceal bleeding can be a gunshot for kidneys.
    Liver Int, 25(3): 527-35. [Abstract] [Full-text]
26. Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C.
    Liver Int, 25(3): 518-26. [Abstract] [Full-text]
27. Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis.
    Liver Int, 25(3): 513-7. [Abstract] [Full-text]
28. Equilibrium of acidifying and alkalinizing metabolic acid-base disorders in cirrhosis.
    Liver Int, 25(3): 505-12. [Abstract] [Full-text]
29. Liver transplantation in patients with hepatic hydrothorax.
    Transpl Int, 18(6): 672-5. [Abstract] [Full-text]
30. Hepatorenal syndrome.
    Dig Dis, 23(1): 47-55. [Abstract] [Full-text]
31. Spontaneous bacterial peritonitis.
    Dig Dis, 23(1): 39-46. [Abstract] [Full-text]
32. Refractory ascites.
    Dig Dis, 23(1): 30-8. [Abstract] [Full-text]
33. Liver transplantation for hepatocellular carcinoma in cirrhosis: prognostic parameters.
    Transplant Proc, 37(4): 1693-4. [Abstract] [Full-text]
34. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
    Transplant Proc, 37(4): 1691-2. [Abstract] [Full-text]
35. Long-term immunosuppression for prevention of nonviral disease recurrence.
    Transplant Proc, 37(4): 1671-4. [Abstract] [Full-text]
36. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.
    Hepatology, 41(6): 1305-12. [Abstract] [Full-text]
37. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.
    Hepatology, 41(6): 1376-82. [Abstract] [Full-text]
38. An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis.
    Hepatology, 41(6): 1262-71. [Abstract] [Full-text]
39. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis.
    Hepatology, 41(6): 1329-38. [Abstract] [Full-text]

© 2004-2008 Liver Cirrhosis Research Today. All Rights Reserved.